Tocilizumab is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis.
It binds soluble as well as membrane bound interleukin-6 receptors, hindering IL-6 from exerting its pro-inflammatory effects.
It is administered through intravenous infusion every month or subcutaneously every 2 weeks.
In 2016, it sold €125 million in Europe.
It has an immunogenicity rate of 0-16%.
Labs that test for drug level:
Labs that test for ADA titre: